Efficacy of zanubrutinib versus acalabrutinib for relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC).

Ther Adv Med Oncol · 2025 · PMC12246662 · PMID 40656602

Europe PMC DOI

hedged sentence

0.0575

closest p · 1.1× alpha

0.0575

boldest claim

The sentences

showed a trendp = 0.0575so close (0.05 < p ≤ 0.1)

Results: Post-matching, PFS-INV was improved significantly for zanubrutinib versus acalabrutinib (hazard ratio (HR) = 0.68 (95% confidence interval (CI): 0.46–0.99); p = 0.0448) and OS showed a trend toward improvement for zanubrutinib (HR = 0.60; 95% CI: 0.35–1.02, p = 0.0575).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.